Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$5.20 USD
-0.15 (-2.80%)
Updated Apr 26, 2024 03:09 PM ET
After-Market: $5.11 -0.09 (-1.73%) 7:44 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
APRE 5.20 -0.15(-2.80%)
Will APRE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for APRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APRE
Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
APRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies
Other News for APRE
Aprea Therapeutics’ Promising Cancer Drug Candidate Warrants Buy Rating
Optimistic Outlook for Aprea Therapeutics’ Oncology Pipeline: A Comprehensive Buy Rating Analysis
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Aprea Therapeutics files to sell 4.39M shares of common stock for holders